trending Market Intelligence /marketintelligence/en/news-insights/trending/jtz2b532w1B-ckHnMwNG1g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Tandem Diabetes' automated insulin delivery system gets FDA approval

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Tandem Diabetes' automated insulin delivery system gets FDA approval

Tandem Diabetes Care Inc.'s system for automated insulin delivery was approved by the U.S. Food and Drug Administration, the first device of its kind that can be used with other diabetes devices.

Tandem's Diabetes Care Control-IQ Technology connects a controller, an insulin pump and a continuous glucose monitor — collectively called an automated insulin dosing system — allowing automatic adjustments of the insulin dose based on blood glucose readings and a history of insulin delivery.

The insulin dosing system was evaluated under the FDA's de novo premarket review pathway, which allows submission for regulatory approval of novel, low-to-moderate-risk devices of a new type. The agency also established criteria outlining requirements for device safety, effectiveness, reliability, device interoperability, cybersecurity and clinical relevance.

San Diego-based Tandem is a medical equipment company that develops products for patients with insulin-dependent diabetes. The company received an approval in February for the insulin pump t:slim X2, an interoperable pump that can securely communicate with compatible automated insulin dosing systems, continuous glucose monitors and other electronic devices used for diabetes management.